Celiac disease rarely travels alone. For a meaningful subset of patients, inflammatory bowel disease—Crohn’s disease or ulcerative colitis—is part of the picture too. What no one has fully mapped, until now, is how carrying both diagnoses actually changes the course of IBD over time. A new study published in Therapeutic Advances in Gastroenterology by Spain’s GETECCU consortium—one of Europe’s largest IBD research networks—takes on exactly that question.
The CEL_EII study draws on data from more than twenty gastroenterology units across Spain. That scale matters. Single-center studies of rare overlapping conditions are prone to noise; a multicenter cohort this large gives researchers enough patients to detect real patterns in how celiac disease shapes the trajectory of IBD.
What This Means for You
If your family is managing celiac disease, IBD may feel like a separate concern. But the two conditions share immune pathways, affect the same digestive tract, and can complicate each other’s diagnosis and treatment. For families like mine, the implications run deeper than statistics.
For one thing, IBD symptoms—chronic diarrhea, abdominal pain, weight loss, fatigue—overlap almost completely with untreated celiac disease. That overlap creates diagnostic delay in both directions. A child or adult with undiagnosed celiac disease can spend years accumulating an IBD workup, and a patient with controlled IBD who develops celiac disease may have their new symptoms attributed to an IBD flare. Tracking how the two conditions interact clinically is the first step toward better diagnostic pathways for patients caught in this overlap.
The practical stakes here are real. IBD management increasingly relies on biologic therapies—powerful immune-suppressing medications. If celiac disease changes how IBD responds to those treatments, or accelerates disease progression toward surgery, clinicians need to know. Research like this feeds directly into treatment decisions at the GI clinic level. It helps gastroenterologists ask the right questions—including whether their IBD patient should be screened for celiac disease at all.
I want my son’s care team to operate with the most complete picture possible. Every study that clarifies how immune-mediated conditions interact brings that picture into sharper focus.
Key Takeaways
- Celiac disease and IBD—Crohn’s disease and ulcerative colitis—can and do co-occur in the same patient, and the overlap is more common than many families realize.
- The CEL_EII study is one of the largest multicenter investigations to date of how celiac disease specifically affects the clinical course of IBD.
- Both conditions share immune-system pathways, which means having one can influence how the other behaves over time.
- Symptom overlap between untreated celiac disease and IBD flares can delay accurate diagnosis of either condition.
- This research supports the case for routine celiac screening in IBD patients—a practice that remains inconsistent across care settings.
The Science
Want to understand how these two conditions interact at a biological level? The connections run deep. Here’s a plain-language walkthrough of the mechanisms involved.
Two Immune Conditions, One Digestive Tract
Inflammatory bowel disease (IBD) is an umbrella term for two chronic conditions: Crohn’s disease, which can affect any part of the GI tract and often involves deep, patchy inflammation, and ulcerative colitis, which causes continuous inflammation confined to the colon. Both involve an overactive immune response that damages the intestinal lining.
Celiac disease works through a different but related immune mechanism: exposure to gluten triggers an abnormal immune reaction that damages the villi (tiny finger-like projections lining the small intestine that absorb nutrients). Over time, that damage reduces nutrient absorption and drives systemic inflammation.
The overlap between celiac disease and IBD is not coincidental. Both are classified as immune-mediated inflammatory diseases—conditions where the body’s immune system attacks its own tissues. Celiac disease belongs to the same broader disease family as Crohn’s, ulcerative colitis, type 1 diabetes, and rheumatoid arthritis. Shared genetic risk factors, particularly variants in HLA genes (proteins that help the immune system recognize self from foreign), mean that people predisposed to one immune-mediated condition often carry elevated risk for others.
This is territory we touched on in our coverage of pediatric celiac disease and coexisting immune-mediated conditions, which documented how frequently celiac appears alongside autoimmune diagnoses in children. IBD fits squarely in that pattern.
Why “Clinical Course” Is the Right Question
Previous research established that celiac disease and IBD co-occur more often than chance alone would predict. What remained unclear was the consequence of that co-occurrence: does having celiac disease change how IBD progresses?
In IBD research, clinical course refers to how a patient’s disease behaves over time—whether it stays mild or escalates, whether it requires biologic therapy (medications like TNF inhibitors or integrin blockers that suppress specific immune pathways), whether it leads to surgery, and how often flares occur. These outcomes matter enormously to patients and families. A worse clinical course means more hospitalizations, more medication adjustments, and more disruption to daily life.
The CEL_EII study’s strength lies in its design. By pulling data across more than twenty Spanish hospitals through the GETECCU consortium—Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa, the Spanish working group on Crohn’s disease and ulcerative colitis—researchers assembled a cohort large enough to isolate the specific effect of concurrent celiac disease on IBD outcomes, controlling for other variables.
The Gluten-Free Diet as a Variable
One underappreciated complexity in this research space is the gluten-free diet (GFD) itself. For celiac patients, strict GFD is the only treatment—it’s non-negotiable. But for IBD patients who also have celiac disease, the GFD introduces a dietary variable that may independently influence intestinal inflammation. Some researchers have explored whether GFD has anti-inflammatory effects in IBD patients beyond its role in celiac management; the evidence is still developing. A large real-world cohort study like CEL_EII, which tracks patients over time in clinical practice, can surface signals about whether GFD adherence in the celiac-plus-IBD group correlates with better or worse IBD outcomes.
Diagnostic Interference
There is also a diagnostic interference problem worth understanding. The main tools gastroenterologists use to assess IBD activity—endoscopy (camera examination of the GI tract), fecal calprotectin (a stool marker of intestinal inflammation), and CRP (C-reactive protein, a blood marker of systemic inflammation)—cannot always distinguish between active IBD and active celiac disease. A patient who is eating gluten and experiencing celiac-driven intestinal damage may appear, on tests, to be in an IBD flare. That misattribution can lead to unnecessary escalation of IBD therapy when what the patient actually needs is better GFD adherence.
Research that characterizes this population helps clinicians build better protocols—including knowing when to test an IBD patient for celiac disease in the first place.
Related Coverage
References
Alonso-Abreu I, Ramos L, Hernandez-Camba A, et al. Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU. Therapeutic Advances in Gastroenterology. 2026 Jun 23:19:17562848261452511. doi: 10.1177/17562848261452511. PubMed
This article is for informational purposes only and does not constitute medical advice. Always consult your gastroenterologist or healthcare provider about your specific situation.